Laurus Labs in South Africa

Laurus Labs’ Strategic Expansion in South Africa: A Milestone in HIV Treatment Accessibility

Johannesburg, South Africa – July 28, 2025

Hyderabad-based pharmaceutical company Laurus Labs has significantly bolstered its presence in South Africa’s healthcare sector through strategic acquisitions and partnerships aimed at enhancing the accessibility of HIV treatments.

Acquisition of Aspen Pharmacare’s Subsidiary

In September 2019, Laurus Labs acquired Phekolong Pharmaceuticals Pty Ltd, a wholly owned subsidiary of Aspen Pharmacare, for ZAR 75,000. This acquisition granted Laurus Labs direct access to the South African public antiretroviral (ARV) sector, which manages one of the world’s largest public ARV programs. While Aspen continued to manufacture the finished dosage forms of ARVs, distribution to the public sector was managed through Laurus Labs’ newly acquired subsidiary. (thehindubusinessline.com)

Launch of Emdolten: A Collaborative Effort

In December 2018, Laurus Labs, in collaboration with Aspen Pharmacare, launched Emdolten, a new HIV drug in South Africa. Emdolten is a triple-combination therapy comprising tenofovir disoproxil fumarate, lamivudine, and dolutegravir. This initiative aimed to provide more effective treatment options to the South African population, aligning with the country’s efforts to combat the HIV epidemic. (thehindubusinessline.com)

Addressing Funding Concerns

In January 2025, Laurus Labs addressed concerns regarding the temporary freeze of funding under the U.S. President’s Emergency Plan for AIDS Relief (PEPFAR). The company clarified that this development was unlikely to significantly impact its business operations, as the ARV market constitutes a small portion of the overall HIV financing budget. Laurus Labs expressed confidence that its operations and business would not face significant disruption due to this temporary funding review. (businessupturn.com)

Ongoing Commitment to HIV Treatment Accessibility

Laurus Labs’ strategic initiatives in South Africa underscore its commitment to enhancing the accessibility and affordability of HIV treatments. Through acquisitions, partnerships, and proactive measures to address funding challenges, Laurus Labs continues to play a pivotal role in supporting South Africa’s efforts to provide comprehensive HIV care to its population.

For more information, please visit Laurus Labs’ official website.